Biopharmaceutical, Vector, Strain, Process and Product development

Nature Technology Corporation is a discovery-based bioengineering technology company, providing industry solutions for biopharmaceutical development: vectors; strains; processes; and products; including manufacturing and technology transfer. NTC specializes in services for manufacturing recombinant plasmids (gene therapeutics and DNA vaccines) and proteins.

Biopharmaceuticals are the fastest growing and most promising of new drug entities. Unlike small molecules, biologics are created in living cells and are designed to function in a highly specific manner. Rational design and advanced molecular technology (Gene Self Assembly, GENSA) has led to highly effective viral and non-viral vectors, designer proteins, gene therapeutics and DNA vaccines. Advanced strain engineering technology (Genome Mass Transfer, GMT) allows specialty microbial genomes to be created from existing host strains, incorporating the genetic and regulatory elements for highest-yield production and simplified processing. Process development creates and integrates essential engineering components of upstream (fermentation) and downstream (purification) technologies, resulting in highest-purity and greatest-yield products.

Tech transfer completes the cycle by integrating production technologies into client or CMO facilities for quality manufacturing of safe and effective biologics. NTC offers highly purified custom plasmid DNA manufacturing and recombinant protein production services.

Call to speak with an NTC specialist, today!

1(888) WIZ-BANG

NTC's 1 minute informational video
 Click to Replay Video
(click on video to stop)

Recent Publications/Press

NTC's 2009 Spring/Summer
Newsletter

Articles:

• Autolytic strains for E. coli
• Antibiotic Free Plasmids
• NTC Waisman Team up
• Rig-1 Activating DNA Vaccines
• Vectors, Initial and Success Limiting
• NTC Publications
• When and Why to outsource
• DNA free Taq DNA Polymerase
June 20, 2009

Improved antibiotic free DNA vaccine vectors utilizing a novel RNA based plasmid selection system Luke, JM Carnes, AE, Hodgson, CP, Williams, JA, (Vaccine, in press) 2009

Co expressed RIG-1 agonist enhances antigen-specificimmune responses to influensa DNA vaccine Methods to increase DNA vaccine induced innate immune responses to improve adaptive immunity are needed. 2009

Plasmid DNA production combining antibiotic-free selection, inducible high yield fermentation, and novel autolytic purification Batch fermentation processes DNA vaccines have tremendous potential for rapid deployment in pandemic applications, wherein a new antigen is plugged into a validated vector, and rapidly produced in a validated, fermentation - purification process. (Biotechnol. Bioeng. 103: 1129-1143) April 3, 2009

Low metabolic burden plasmid production Nature Technology’s DNA Manufacturing Platform Tackles Instability and Toxicity Issues (Gen. Eng. News, Vol. 29, No. 5) March 1, 2009

Strain engineering by genome mass transfer: efficient chromosomal trait transfer method utilizing donor genomic DNA and recipient recombineering hosts (Mol. Biotechnol., in press), DOI 10.1007/s12033-009-9177-5. 2009

Plasmid DNA vaccine vector design: Impact on efficacy, safety and upstream production Critical molecular and cellular biological factors impacting design of licensable DNA vaccine vectors that combine high yield and integrity during bacterial production with increased expression in mammalian cells are reviewed, (Biotechnol Adv., 27:353-370) February 7, 2009

Meetings

DNA Vaccines, New Orleans, LA
JMarch 2-4, 2010

BIO2010, Chicago, McCormick Place
May 3-6

ASGT-American Society for Gene Therapy:Washington DC
May 17-22, 2010 (NTC Booth)


Vaccine Technology III, Puerto Vallarta, MX
June 6-1, 2010 (NTC Booth)

Partnering Opportunities